Vaccines against persistent DNA virus infections

被引：5

作者：

Wills, MR ^{[1
]}

Carmichael, AJ ^{[1
]}

Sissons, JGP ^{[1
]}

机构：

[1] Univ Cambridge, Sch Clin Med, Dept Med, Cambridge, England

来源：

BRITISH MEDICAL BULLETIN | 2002年 / 62卷

关键词：

D O I：

10.1093/bmb/62.1.125

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Persistent viruses present some particular problems for vaccine design. As for acute non-persistent viruses, the prime goal of a vaccine should be to prevent primary infection. Vaccines might also be used to modify the course of established persistent virus infections - so-called postinfective immunisation. This chapter deals with selected persistent DNA viruses, in particular the human herpes viruses.

引用

页码：125 / 138

页数：14

共 53 条

[11] Construction and characterization of a replication-defective herpes simplex virus 2 ICP8 mutant strain and its use in immunization studies in a guinea pig model of genital disease [J].

DaCosta, XJ ;

Bourne, N ;

Stanberry, LR ;

Knipe, DM .

VIROLOGY, 1997, 232 (01) :1-12

[12] ANALYSIS OF THE PROLIFERATIVE T-CELL RESPONSE TO HUMAN CYTOMEGALOVIRUS MAJOR IMMEDIATE-EARLY PROTEIN (IE1) - PHENOTYPE, FREQUENCY AND VARIABILITY [J].

DAVIGNON, JL ;

CLEMENT, D ;

ALRIQUET, J ;

MICHELSON, S ;

DAVRINCHE, C .

SCANDINAVIAN JOURNAL OF IMMUNOLOGY, 1995, 41 (03) :247-255

[13] CONSEQUENCES OF VARICELLA AND HERPES-ZOSTER IN PREGNANCY - PROSPECTIVE-STUDY OF 1739 CASES [J].

ENDERS, G ;

MILLER, E ;

CRADOCKWATSON, J ;

BOLLEY, I ;

RIDEHALGH, M .

LANCET, 1994, 343 (8912) :1548-1551

[14] Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization [J].

Endresz, V ;

Kari, L ;

Berencsi, K ;

Kari, C ;

Gyulai, Z ;

Jeney, C ;

Pincus, S ;

Rodeck, U ;

Méric, C ;

Plotkin, SA ;

Gönczöl, E .

VACCINE, 1999, 17 (01) :50-58

[15] Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: A potential treatment strategy for Epstein-Barr virus-positive Hodgkin's lymphoma [J].

Gahn, B ;

Siller-Lopez, F ;

Pirooz, AD ;

Yvon, E ;

Gottschalk, S ;

Longnecker, R ;

Brenner, MK ;

Heslop, HE ;

Aguilar-Cordova, E ;

Rooney, CM .

INTERNATIONAL JOURNAL OF CANCER, 2001, 93 (05) :706-713

[16] Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract [J].

Gallichan, WS ;

Woolstencroft, RN ;

Guarasci, T ;

McCluskie, MJ ;

Davis, HL ;

Rosenthal, KL .

JOURNAL OF IMMUNOLOGY, 2001, 166 (05) :3451-3457

[17] Development of a cytomegalovirus vaccine: lessons from recent clinical trials [J].

Gonczol, E ;

Plotkin, S .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2001, 1 (03) :401-412

[18]

GU SY, 1995, DEV BIOL STAND, V84, P171

[19] THE INCIDENCE OF ZOSTER AFTER IMMUNIZATION WITH LIVE ATTENUATED VARICELLA VACCINE - A STUDY IN CHILDREN WITH LEUKEMIA [J].

HARDY, I ;

GERSHON, AA ;

STEINBERG, SP ;

LARUSSA, P .

NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (22) :1545-1550

[20] Prevalence of postherpetic neuralgia after a first episode of herpes zoster: prospective study with long term follow up [J].

Helgason, S ;

Petursson, G ;

Gudmundsson, S ;

Sigurdsson, JA .

BRITISH MEDICAL JOURNAL, 2000, 321 (7264) :794-796A

← 1 2 3 4 5 6 →